Full Press Release Details
Tiziana Life Science Plc (the "Company")
Proposed Cancellation from AIM
York/London, 13 January 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing
on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that it has appointed
advisers in relation to an intended redomicile of the Company to Bermuda which is anticipated to occur by Q2-2020, as a consequence
of the redomicile the Company will not be seeking to re-admit its ordinary shares on AIM and will therefore seek shareholder consent
for its shares to be cancelled from AIM when the redomicile occurs. A further announcement will be made in due course.
Furthermore, the Company intends to cancel
its ADR program and have its Bermuda common shares listed on Nasdaq.
The Company is today attending the J.P.
Morgan Healthcare Conference in San Francisco, a copy of the investor presentation that is being used by the Company is available
for download from its website at www.tizianalifesciences.com.
About Tiziana Life Sciences
Tiziana is a UK biotechnology company that
focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to milciclib,
the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 mAbs in clinical development
in the world. This compound has potential application in a wide range of autoimmune and inflammatory diseases, such as crohn's
disease (CD), nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1
diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is
For more information go to http://www.tizianalifesciences.com
The person who arranged for the release
of this announcement on behalf of the Company was Kunwar Shailubhai, CEO of Tiziana.
| Tiziana Life Sciences plc | |
| Gabriele Cerrone, Chairman and founder | +44 (0)20 7495 2379 |
| Cairn Financial Advisers LLP (Nominated adviser) | +44 (0)20 7213 0883 |
| Liam Murray / Jo Turner |
| Shore Capital (Broker) | +44 (0)20 7408 4050 |
| Antonio Bossi / Fiona Conroy |